Mathew Tollefson
Papers
6
Total Citations
938
H-Index
5
About
Dr. Mathew Tollefson is a leading urologic oncologist and surgeon whose research has fundamentally shaped the surgical treatment of bladder cancer. As the principal investigator of the landmark RAZOR trial, he led the first multi-institutional, phase 3 randomized comparison of robot-assisted versus open radical cystectomy. His seminal 2018 paper in *The Lancet* (760 citations) established that robotic surgery is non-inferior to open surgery for 2-year progression-free survival, a finding that transformed clinical practice. Dr. Tollefson’s subsequent work extended these insights, demonstrating comparable 3-year survival outcomes (115 citations) and critically evaluating health-related quality of life and functional independence recovery. His research has provided the highest-level evidence that robotic cystectomy offers equivalent oncologic control with potential advantages in recovery and patient-reported outcomes. Beyond bladder cancer, Dr. Tollefson has also pioneered the application of the da Vinci SP single-port system for complex reconstructive procedures. Through the RAZOR trial and his ongoing investigations into postoperative complications and readmission rates, he continues to define the evidence base for minimally invasive urologic surgery, directly impacting how surgeons counsel patients and choose surgical approaches.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5
- 6